Absolute Neutrophil Count after the First Chemotherapy Cycle as a Surrogate Marker for Treatment Outcomes in Patients with Neuroblastoma

PURPOSE: We performed this study to determine whether the degree of neutropenia after the first chemotherapy cycle can be used as a surrogate marker of individual susceptibility to chemotherapeutic agents affecting treatment outcome in patients with neuroblastoma. MATERIALS AND METHODS: The study in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Ji Won, Bae, Joon Seol, Kim, Jin Ho, Cho, Hee Won, Ju, Hee Young, Yoo, Keon Hee, Koo, Hong Hoe, Woo, Sook-young, Kim, Seonwoo, Sung, Ki Woong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756108/
https://www.ncbi.nlm.nih.gov/pubmed/33848412
http://dx.doi.org/10.4143/crt.2021.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756108/
https://www.ncbi.nlm.nih.gov/pubmed/33848412
http://dx.doi.org/10.4143/crt.2021.010

Ejemplares similares